- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02860806
Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults
January 26, 2018 updated by: Janssen-Cilag International NV
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Absolute Bioavailability of JNJ-63623872 Administered as an Intravenous Infusion and a 600-mg Oral Dose in Healthy Adult Subjects
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) of single escalating intravenous (IV) doses of JNJ-63623872 administered as a continuous infusion; to evaluate the safety and tolerability of single escalating IV doses of JNJ-63623872 administered as a continuous infusion; to characterize the single-dose PK of JNJ-63623872 of one selected dose administered as a continuous IV infusion at various durations and to characterize the single- and repeat-dose PK of JNJ-63623872 administered as a continuous infusion.
Study Overview
Study Type
Interventional
Enrollment (Actual)
66
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Merksem, Belgium
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A female participant (except if postmenopausal) must have a negative serum beta- human chorionic gonadotropin (beta-hCG) pregnancy test at screening and on Day -1 of each treatment period
- A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 90 days after discontinuation of study drug
- During the study and for a minimum of 1 spermatogenesis cycle (defined as approximately 90 days) after receiving the last dose of study drug, in addition to the highly effective method of contraception in the female partner, a man regardless of having been vasectomized: 1) who is sexually active with a woman of childbearing potential must agree to use a barrier method of contraception (example, condom with spermicidal foam/gel/film/cream/suppository), 2) must agree not to donate sperm and 3) who is sexually active with a pregnant women must use a condom
- Must have a Body Mass Index (BMI); weight kilogram [kg]/height^2 [m]^2) between 18.0 and 30.0 kilogram per meter square (kg/m^2) (extremes included) at Screening
- Must have a blood pressure (supine after at least 5 minutes rest and standing after at least 1 minute standing) between 90 and 140 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic at Screening
Exclusion Criteria:
- Has a history of current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
- With a past history of heart arrhythmias (extrasystoli, tachycardia at rest), history of risk factors for Torsade de Pointes syndrome (example, hypokalemia, family history of long QT Syndrome)
- Has known allergies, hypersensitivity, or intolerance to JNJ-63623872 or its excipients
- With any history of clinically significant skin disease such as, but not limited to, dermatitis, eczema, drug rash, psoriasis, food allergy, or urticaria
- With a history of clinically significant drug allergy such as, but not limited to, sulfonamides and penicillins, or drug allergy diagnosed in previous studies with experimental drugs
- Has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at Screening
- Has a history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at Screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Period 1 (JNJ-63623872 100 mg or Placebo)
Participants will receive a single intravenous (IV) infusion of JNJ-63623872 100 milligram (mg) [3 milligram per milliliters (mg/mL) solution] (Treatment A) or matching placebo (Treatment D) over 120 minutes.
|
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
Intravenous infusion of matching placebo.
|
Experimental: Part 1: Period 2 (JNJ-63623872 200 mg or Placebo)
Participants will receive a single IV infusion of JNJ-63623872 200 mg (3 mg/mL solution) (Treatment B) or matching placebo (Treatment D) over 120 minutes.
|
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
Intravenous infusion of matching placebo.
|
Experimental: Part 1: Period 3 (JNJ-63623872 300 mg or Placebo)
Participants will receive a single IV infusion of JNJ-63623872 300 mg (3 mg/mL solution) (Treatment C) or matching placebo (Treatment D) over 120 minutes.
|
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
Intravenous infusion of matching placebo.
|
Experimental: Part 2: Group 1 (EFG)
Participants will receive a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over x minutes (Treatment E) followed by a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over y minutes (Treatment F), then a single oral 600-mg dose (2* 300 mg tablets) of JNJ-63623872 under fasted conditions (Treatment G).
Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
|
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
|
Experimental: Part 2: Group 2 (FGE)
Participants will receive Treatment F, then Treatment G followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
|
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
|
Experimental: Part 2: Group 3 (GEF)
Participants will receive Treatment G, then Treatment E followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
|
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
|
Experimental: Part 2: Group 4 (GFE)
Participants will receive Treatment G, then Treatment F, followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
|
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
|
Experimental: Part 2: Group 5 (FEG)
Participants will receive Treatment F, then Treatment E followed by Treatment G. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
|
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
|
Experimental: Part 2: Group 6 (EGF)
Participants will receive Treatment E, then Treatment G followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
|
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
|
Experimental: Part 3: JNJ-63623872 300 mg
Participants will receive multiple IV infusions of JNJ-63623872 300 mg (3 mg/mL) solution every 12 hours on Days 1 to 10, with only a morning dose on Day 10.
Duration of infusion and dose will be selected after Part 2 of this study is completed.
|
3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Analyte Concentration (Cmax)
Time Frame: Up to 10 days
|
The Cmax is the maximum observed analyte concentration.
|
Up to 10 days
|
Fluctuation Index (FI)
Time Frame: Up to 10 days
|
FI is defined as the percentage fluctuation between the Ctrough, morning analyte concentration and the maximum analyte concentration.
|
Up to 10 days
|
Average Analyte Concentration (Cavg)
Time Frame: Up to 10 days
|
The Cavg is an average analyte concentration at steady-state over the dosing interval.
|
Up to 10 days
|
Time to Reach the Maximum Observed Analyte Concentration (Tmax)
Time Frame: Up to 10 days
|
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
|
Up to 10 days
|
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to 12 Hour (AUC [0-12])
Time Frame: Up to 10 days
|
The (AUC [0-12]) is the area under the plasma concentration-time curve from time 0 to 12 hour post dose, calculated by linear-linear trapezoidal summation.
|
Up to 10 days
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC [0-last])
Time Frame: Up to 10 days
|
The (AUC [0-last]) is the area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable (non-below quantification limit [non-BQL]) concentration, calculated by linear-linear trapezoidal summation.
|
Up to 10 days
|
Area Under the Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])
Time Frame: Up to 10 days
|
The AUC (0-infinity) is the area under the plasma concentration-time curve from time 0 to infinity, calculated as the sum of AUC(last) and C(last)/lambda(z), where Clast is the last observed measurable (non-BQL) concentration; extrapolations of more than 20.00 percent (%) of the total AUC are reported as approximations.
|
Up to 10 days
|
Elimination Rate Constant (Lambda[z])
Time Frame: Up to 10 days
|
Lambda(z) is apparent terminal elimination rate constant, determined by linear regression using the terminal log-linear phase of the log transformed concentration-time curve.
|
Up to 10 days
|
Apparent Terminal Elimination Half-life (t1/2term)
Time Frame: Up to 10 days
|
Apparent terminal elimination half-life is defined as 0.693/Lambda[z].
|
Up to 10 days
|
Systemic Clearance (CL)
Time Frame: Up to 10 days
|
CL is the total systemic clearance, following intravenous administration.
|
Up to 10 days
|
Apparent Clearance (CL/F)
Time Frame: Up to 10 days
|
CL/F is the total apparent clearance, following extravascular administration.
|
Up to 10 days
|
Volume of Distribution (Vd)
Time Frame: Up to 10 days
|
The Vd is defined as volume of distribution, following single dose intravenous administration.
|
Up to 10 days
|
Apparent Volume of Distribution (Vd/F)
Time Frame: Up to 10 days
|
Vd/F is defined as apparent volume of distribution, following single dose extravascular administration.
|
Up to 10 days
|
Volume of Distribution at Steady-State (Vss)
Time Frame: Up to 10 days
|
Vss is defined as apparent volume of distribution at steady-state following intravenous administration.
|
Up to 10 days
|
Observed Accumulation Index (RA abs)
Time Frame: Up to 10 days
|
Observed Accumulation Index is calculated by AUC12h, steady state/(AUC12h, single dose).
|
Up to 10 days
|
Morning Trough Analyte Concentration (Ctrough, morning)
Time Frame: Up to 10 days
|
Ctrough, morning is defined as observed analyte concentration just prior to the beginning of a dosing interval.
|
Up to 10 days
|
Evening Trough Analyte Concentration (Ctrough, evening)
Time Frame: Up to 10 days
|
Ctrough, evening is defined as observed analyte concentration at the end of a dosing interval.
|
Up to 10 days
|
Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability
Time Frame: Up to End of Study (Day 14)
|
Up to End of Study (Day 14)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute Bioavailability (F[abs])
Time Frame: Up to 10 days
|
The F(abs) is calculated as AUC (0-infinity), oral/ AUC (0-infinity), intravenous (iv)*Dose, iv/Dose, oral*100 %, where AUC (0-infinity) is area under the concentration-time curve from time zero to extrapolated infinite time, and D is the dose of administered drug.
|
Up to 10 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 8, 2016
Primary Completion (Actual)
June 6, 2017
Study Completion (Actual)
June 10, 2017
Study Registration Dates
First Submitted
August 5, 2016
First Submitted That Met QC Criteria
August 5, 2016
First Posted (Estimate)
August 9, 2016
Study Record Updates
Last Update Posted (Actual)
January 30, 2018
Last Update Submitted That Met QC Criteria
January 26, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- CR108196
- 63623872FLZ1002 (Other Identifier: Janssen-Cilag International NV)
- 2016-000921-37 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on JNJ-63623872
-
Janssen Cilag N.V./S.A.Completed
-
Janssen Infectious Diseases BVBACompleted
-
Janssen-Cilag International NVTerminatedKidney Failure, ChronicGermany
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCNo longer availableH7N9 Subtype of Influenza A Virus
-
Janssen-Cilag International NVCompletedHepatic ImpairmentGermany
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCTerminatedInfluenza AUnited States, France, Korea, Republic of, Taiwan, China, India, Argentina, Israel, Thailand, Vietnam, Hungary, Germany, South Africa, Spain, Turkey, Belgium, Brazil, Canada, Mexico, New Zealand, Bulgaria, Peru, Malaysia, Italy, Estonia, ... and more
-
Yale UniversityPfizer; Avid RadiopharmaceuticalsCompletedDiabetes Mellitus, Type 1United States